# Phase 25 — Final Sale Readiness

## Purpose

Phase 25 is the final repository-level release gate for presenting MediQuery to a technical buyer. It creates a reproducible evidence package; it does not manufacture customers, revenue, clinical validation, regulatory approval, or a transaction.

## Acceptance criteria

- Phases 17 through 24 have passing repository gates.
- The exact release commit is recorded and reproducible.
- A buyer data room index identifies architecture, security, AI safety, deployment, testing, IP, and diligence materials.
- Synthetic-only buyer demonstration steps are documented.
- Release quality requires formatting, linting, tests, compilation, and credential-pattern scanning.
- Medical safety boundaries remain explicit: MediQuery is not a diagnostic service.
- External diligence remains open for IP ownership, customer demand, clinical validation, privacy/legal review, production deployment, and security assurance.
- The release manifest fails closed if required phase gates or evidence are absent.

## Buyer data room

The final package should contain the repository revision, architecture, security and AI safety documents, production-readiness evidence, synthetic evaluation results, deployment requirements, acquisition overview, buyer due-diligence checklist, release checklist, and CI evidence for the exact revision.

## Sale boundary

A passing Phase 25 gate means the engineering asset is organized and demonstrable for diligence. It does **not** establish a $150,000 valuation or guarantee a buyer. Commercial value must be supported by transferable IP, differentiated workflow, customer demand, operating evidence, and strategic fit.

## Release manifest

`src/services/release_manifest.py` provides a fail-closed machine-readable contract requiring an exact revision, passing tests/quality, completed phase gates, an explicit medical safety boundary, and continuing external diligence.

## Final status

Phase 25 closes the repository engineering program. It is the end of the five-phase extension after Phase 20, not a substitute for the external work required to launch real medical-data processing or close an acquisition.
